| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 28.70 | 3.99% | 25.05万 | 7.19亿 | | 600538 | 国发股份 | 6.16 | 1.65% | 11.26万 | 6927.21万 | | 002462 | 第章章 | 14.09 | 1.22% | 3.56万 | 5007.96万 | | 000078 | 海于生物 | 2.62 | 1.16% | - 33.77万 | 8793.03万 | | 301015 | 百洋医药 | 31.29 | 0.84% | 9.83万 | 3.05亿 | | 600713 | 南京医药 | 5.01 | 0.80% | 15.62万 | 7796.73万 | | 301126 | 达嘉维康 | 11.92 | 0.68% | 2.86万 | 3420.67万 | | 000705 | 浙江震元 | 9.60 | 0.63% | 10.21万 | 9780.70万 | | 603122 | 合 ...

证券代码：301015 证券简称：百洋医药 公告编号：2025-078 债券代码：123194 债券简称：百洋转债 青岛百洋医药股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，为满足子公司业务发展的资金需求，青岛百洋医药股份有限公司（以下 简称"公司"）为全资子公司北京百洋智合医学成果转化服务有限公司（以下简称 "百洋智合"）的授信额度提供了连带责任保证担保。具体情况如下： 近日，为满足日常经营资金需求，百洋智合向招商银行股份有限公司北京分行 （以下简称"招商银行"）申请了综合授信额度。为支持子公司的业务发展，公司 出具了《最高额不可撤销担保书》，为上述授信额度提供连带责任保证担保，担保 授信本金余额最高限额为人民币 3,000 万元。本次担保事项在前述担保额度范围内， 无需另行召开董事会及股东大会审议。 本次担保前公司对百洋智合已提供且尚在担保期限内的担保余额为5,000万元； 本次担保后公司对百洋智合已提供且尚在担保期限内的担保余额为 6,010 万元，百 洋智合可用担保额度为 12,000 万元。 注： ...

近日，中山莱博瑞辰生物医药有限公司与百洋医药集团、东方晨星、圣诺生物、成海创投等投资方完成 签约和交割，超募完成A++轮融资。本轮融资由百洋医药集团领投，东方晨星、圣诺生物、成海创投跟 投，此外，老股东珠海一豪也继续追加了投资。本轮资金将重点用于推进管线RAB001d和RAB202项 目，同时夯实公司技术平台和团队建设。 ...

证券之星消息，9月8日医药商业板块较上一交易日上涨1.96%，百洋医药领涨。当日上证指数报收于 3826.84，上涨0.38%。深证成指报收于12666.84，上涨0.61%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 301015 百洋医药 | | 4764.84万 | 10.90% | 1855.94万 | 4.25% | -6620.78万 | -15.15% | | 600829 人民同泰 | | 894.41万 | 7.05% | -981.04万 | -7.73% | 86.63万 | 0.68% | | 600713 南京医药 | | 702.19万 | 9.22% | 5.30万 | - 0.07% | -707.48万 | -9.29% | | 002727 | 一心堂 | 428.36万 | 2.06% | -1164.56万 | -5.61% | 736.21万 ...

证券日报网讯百洋医药（301015）9月8日在互动平台回答投资者提问时表示，净利润增速下降主要是公 司向创新战略转型，公司为拓展创新业务新招募的创新药人员以及前期推广费用导致公司费用支出增 加；迪巧销售渠道正向线上迁移。未来随着新业务的逐步放量，收入结构会不断优化。 ...

Market Performance - The pharmaceutical commercial sector increased by 0.4% compared to the previous trading day, with Baiyang Pharmaceutical leading the gains [1] - On the same day, the Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Individual Stock Performance - Baiyang Pharmaceutical (301015) closed at 27.16, with a rise of 4.14% and a trading volume of 108,200 shares, amounting to a transaction value of 287 million yuan [1] - Other notable performers included Guofang Co. (600538) with a 2.14% increase, and Runda Medical (603108) with a 1.79% increase [1] - Conversely, Selin Medical (603716) saw a decline of 1.21%, with a trading volume of 289,200 shares and a transaction value of 809 million yuan [2] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 16.35 million yuan from institutional investors, while retail investors saw a net inflow of 11.97 million yuan [2] - The data indicates that retail investors are showing interest in the sector despite the overall net outflow from institutional investors [2] Detailed Capital Flow for Selected Stocks - Runda Medical (603108) had a net inflow of 16.55 million yuan from institutional investors, while it faced a net outflow of 10.39 million yuan from retail investors [3] - China Medical (600056) also saw significant institutional inflows of 15.68 million yuan, but retail investors withdrew 5.26 million yuan [3] - Baiyang Pharmaceutical (301015) had a net inflow of 12.71 million yuan from institutional investors, with retail investors withdrawing 11.58 million yuan [3]

证券之星消息，9月4日医药商业板块较上一交易日下跌0.07%，塞力医疗领跌。当日上证指数报收于 3765.88，下跌1.25%。深证成指报收于12118.7，下跌2.83%。医药商业板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 29.00 | -2.26% | 25.68万 | 7.59 Z | | 600833 | 第一医药 | 14.19 | -1.39% | 15.14万 | 2.16亿 | | 600829 | 人民同泰 | 8.33 | -1.30% | 12.97万 | 1.09亿 | | 601607 | 上海医药 | 18.26 | -1.19% | 1 20.62万 | 3.77亿 | | 600538 | 国发股份 | 6.07 | -1.14% | 12.97万 | 7917.71万 | | 60 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600713 | 南京医药 | 5.00 | -3.10% | 47.53万 | 2.38亿 | | 301015 | 百洋医药 | 25.92 | -1.82% | 9.08万 | 2.36亿 | | 603716 | 塞力医疗 | 33.53 | -1.24% | 39.83万 | 13.50亿 | | 603939 | 益丰药房 | 23.51 | -0.97% | 13.43万 | 3.17亿 | | 601607 | 上海医药 | 18.49 | -0.96% | 47.89万 | 8.92 Z | | 603883 | 老百姓 | 17.89 | -0.78% | 15.32万 | 2.74亿 | | 000950 | 重药控股 | 5.25 | -0.38% | 21.78万 | 1.14亿 | | 603108 | 润达医疗 | 17.51 | -0.34% | 21.38万 | 3.74亿 | | 301017 | 漱玉平民 | ...

消息面上，北海康成发布中期业绩，上半年收益2224.8万元，同比减少50.33%；期内溢利5923.8万元， 去年同期则取得亏损2.47亿元，实现扭亏为盈。公告称，收入减少主要由于公司原计划于2021年战略性 专注于罕见病，于2024年底贺俪安分销协议终止后贺俪安在中国台湾销售停止。除贺俪安在中国台湾的 销售外，公司收益较2024年同期减少170万元或6.9%，主要由于2025年上半年北海康成实施积极存货管 理，并在渠道中减少迈芮倍的库存。 值得注意的是，2025年8月，北海康成宣布与百洋医药（301015）达成股份认购协议，根据协议，百洋 医药将斥资1亿港元认购北海康成股份。与此同时，北海康成与百洋医药双方通过签订独家商业化服务 协议，进一步深化战略协同。根据协议，百洋医药旗下子公司将获得北海康成旗下特定产品在中国内 地、香港及澳门地区的推广权。 北海康成-B(01228)绩后涨超12%，截至发稿，涨9.48%，报2.54港元，成交额1031.41万港元。 ...

Core Viewpoint - Beihai Kangcheng-B (01228) experienced a significant stock price increase of over 12% following the release of its interim results, indicating positive market sentiment despite a decline in revenue [1] Financial Performance - For the first half of the year, the company reported revenue of 22.248 million, a decrease of 50.33% year-on-year [1] - The company achieved a profit of 59.238 million, compared to a loss of 247 million in the same period last year, marking a turnaround to profitability [1] - Revenue decline was primarily attributed to the company's strategic focus on rare diseases initiated in 2021, with the termination of the distribution agreement for the product "He Li An" in Taiwan by the end of 2024 [1] - Excluding the sales of "He Li An" in Taiwan, the company's revenue decreased by 1.7 million or 6.9% compared to the same period in 2024, mainly due to proactive inventory management and reduced stock of "Mai Ru Bei" in the channels [1] Strategic Developments - In August 2025, the company announced a share subscription agreement with Baiyang Pharmaceutical, where Baiyang will invest 100 million Hong Kong dollars to subscribe for shares in Beihai Kangcheng [1] - The agreement includes an exclusive commercialization service contract, enhancing strategic collaboration between the two companies [1] - A subsidiary of Baiyang Pharmaceutical will gain promotional rights for specific products of Beihai Kangcheng in mainland China, Hong Kong, and Macau [1]